Please share...
The U.S. patent office will review patents on Alexion Pharmaceuticals Inc’s blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.
Patent court to review Alexion’s Soliris patents on Amgen challenge
September 2, 2019By
